Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 35

1.

Small molecule antiviral β-D-N 4-hydroxycytidine inhibits a proofreading-intact coronavirus with a high genetic barrier to resistance.

Agostini ML, Pruijssers AJ, Chappell JD, Gribble J, Lu X, Andres EL, Bluemling GR, Lockwood MA, Sheahan TP, Sims AC, Natchus MG, Saindane M, Kolykhalov AA, Painter GR, Baric RS, Denison MR.

J Virol. 2019 Oct 2. pii: JVI.01348-19. doi: 10.1128/JVI.01348-19. [Epub ahead of print]

PMID:
31578288
2.

The prophylactic and therapeutic activity of a broadly active ribonucleoside analog in a murine model of intranasal venezuelan equine encephalitis virus infection.

Painter GR, Bowen RA, Bluemling GR, DeBergh J, Edpuganti V, Gruddanti PR, Guthrie DB, Hager M, Kuiper DL, Lockwood MA, Mitchell DG, Natchus MG, Sticher ZM, Kolykhalov AA.

Antiviral Res. 2019 Sep 5;171:104597. doi: 10.1016/j.antiviral.2019.104597. [Epub ahead of print]

3.

Development of a novel progesterone analog in the treatment of traumatic brain injury.

Sayeed I, Wali B, Guthrie DB, Saindane MT, Natchus MG, Liotta DC, Stein DG.

Neuropharmacology. 2019 Feb;145(Pt B):292-298. doi: 10.1016/j.neuropharm.2018.09.013. Epub 2018 Sep 14. Review.

PMID:
30222982
4.

Orally Efficacious Broad-Spectrum Ribonucleoside Analog Inhibitor of Influenza and Respiratory Syncytial Viruses.

Yoon JJ, Toots M, Lee S, Lee ME, Ludeke B, Luczo JM, Ganti K, Cox RM, Sticher ZM, Edpuganti V, Mitchell DG, Lockwood MA, Kolykhalov AA, Greninger AL, Moore ML, Painter GR, Lowen AC, Tompkins SM, Fearns R, Natchus MG, Plemper RK.

Antimicrob Agents Chemother. 2018 Jul 27;62(8). pii: e00766-18. doi: 10.1128/AAC.00766-18. Print 2018 Aug.

5.

β-d-N 4-Hydroxycytidine Is a Potent Anti-alphavirus Compound That Induces a High Level of Mutations in the Viral Genome.

Urakova N, Kuznetsova V, Crossman DK, Sokratian A, Guthrie DB, Kolykhalov AA, Lockwood MA, Natchus MG, Crowley MR, Painter GR, Frolova EI, Frolov I.

J Virol. 2018 Jan 17;92(3). pii: e01965-17. doi: 10.1128/JVI.01965-17. Print 2018 Feb 1.

6.

Identification of Non-Nucleoside Inhibitors of the Respiratory Syncytial Virus Polymerase Complex.

Jiménez-Somarribas A, Mao S, Yoon JJ, Weisshaar M, Cox RM, Marengo JR, Mitchell DG, Morehouse ZP, Yan D, Solis I, Liotta DC, Natchus MG, Plemper RK.

J Med Chem. 2017 Mar 23;60(6):2305-2325. doi: 10.1021/acs.jmedchem.6b01568. Epub 2017 Mar 13.

7.

Evaluating the neurotherapeutic potential of a water-soluble progesterone analog after traumatic brain injury in rats.

Wali B, Sayeed I, Guthrie DB, Natchus MG, Turan N, Liotta DC, Stein DG.

Neuropharmacology. 2016 Oct;109:148-158. doi: 10.1016/j.neuropharm.2016.05.017. Epub 2016 Jun 4.

PMID:
27267687
8.

Identification and Characterization of Influenza Virus Entry Inhibitors through Dual Myxovirus High-Throughput Screening.

Weisshaar M, Cox R, Morehouse Z, Kumar Kyasa S, Yan D, Oberacker P, Mao S, Golden JE, Lowen AC, Natchus MG, Plemper RK.

J Virol. 2016 Jul 27;90(16):7368-7387. doi: 10.1128/JVI.00898-16. Print 2016 Aug 15.

9.

Discovery of a Fluorinated Enigmol Analog with Enhanced in Vivo Pharmacokinetic and Anti-Tumor Properties.

Miller EJ, Mays SG, Baillie MT, Howard RB, Culver DG, Saindane M, Pruett ST, Holt JJ, Menaldino DS, Evers TJ, Reddy GP, Arrendale RF, Natchus MG, Petros JA, Liotta DC.

ACS Med Chem Lett. 2016 Mar 21;7(5):537-42. doi: 10.1021/acsmedchemlett.6b00113. eCollection 2016 May 12.

10.

Discovery of tetrahydroisoquinoline-based CXCR4 antagonists.

Truax VM, Zhao H, Katzman BM, Prosser AR, Alcaraz AA, Saindane MT, Howard RB, Culver D, Arrendale RF, Gruddanti PR, Evers TJ, Natchus MG, Snyder JP, Liotta DC, Wilson LJ.

ACS Med Chem Lett. 2013 Sep 5;4(11):1025-30. doi: 10.1021/ml400183q. eCollection 2013 Nov 14.

11.

An orally available, small-molecule polymerase inhibitor shows efficacy against a lethal morbillivirus infection in a large animal model.

Krumm SA, Yan D, Hovingh ES, Evers TJ, Enkirch T, Reddy GP, Sun A, Saindane MT, Arrendale RF, Painter G, Liotta DC, Natchus MG, von Messling V, Plemper RK.

Sci Transl Med. 2014 Apr 16;6(232):232ra52. doi: 10.1126/scitranslmed.3008517.

12.

Synthesis and Metabolic Studies of Host Directed Inhibitors for Anti Viral Therapy.

Moore TW, Sana K, Yan D, Krumm SA, Thepchatri P, Snyder JP, Marengo J, Arrendale RF, Prussia AJ, Natchus MG, Liotta DC, Plemper RK, Sun A.

ACS Med Chem Lett. 2013 Aug 8;4(8):762-767.

13.

Asymmetric synthesis of host-directed inhibitors of myxoviruses.

Moore TW, Sana K, Yan D, Thepchatri P, Ndungu JM, Saindane MT, Lockwood MA, Natchus MG, Liotta DC, Plemper RK, Snyder JP, Sun A.

Beilstein J Org Chem. 2013;9:197-203. doi: 10.3762/bjoc.9.23. Epub 2013 Jan 30.

14.

Water-soluble progesterone analogues are effective, injectable treatments in animal models of traumatic brain injury.

Guthrie DB, Stein DG, Liotta DC, Lockwood MA, Sayeed I, Atif F, Arrendale RF, Reddy GP, Evers TJ, Marengo JR, Howard RB, Culver DG, Natchus MG.

ACS Med Chem Lett. 2012 Mar 15;3(5):362-6. doi: 10.1021/ml200303r. eCollection 2012 May 10.

15.

Non-nucleoside inhibitors of the measles virus RNA-dependent RNA polymerase: synthesis, structure-activity relationships, and pharmacokinetics.

Ndungu JM, Krumm SA, Yan D, Arrendale RF, Reddy GP, Evers T, Howard R, Natchus MG, Saindane MT, Liotta DC, Plemper RK, Snyder JP, Sun A.

J Med Chem. 2012 May 10;55(9):4220-30. doi: 10.1021/jm201699w. Epub 2012 Apr 20.

16.

Sphingolipid analogues inhibit development of malaria parasites.

Meyer EV, Holt JJ, Girard KR, Ballie MT, Bushnev AS, Lapp S, Menaldino DS, Arrendale RF, Reddy GP, Evers TJ, Howard RB, Culver DG, Liotta DC, Galinski MR, Natchus MG.

ACS Med Chem Lett. 2011 Dec 6;3(1):43-7. doi: 10.1021/ml2002136. eCollection 2012 Jan 12.

17.

Novel synthesis and biological evaluation of enigmols as therapeutic agents for treating prostate cancer.

Garnier-Amblard EC, Mays SG, Arrendale RF, Baillie MT, Bushnev AS, Culver DG, Evers TJ, Holt JJ, Howard RB, Liebeskind LS, Menaldino DS, Natchus MG, Petros JA, Ramaraju H, Reddy GP, Liotta DC.

ACS Med Chem Lett. 2011 Mar 25;2(6):438-43. doi: 10.1021/ml2000164. eCollection 2011 Jun 9.

18.

Comparison of the pharmacology of hydroxamate- and carboxylate-based matrix metalloproteinase inhibitors (MMPIs) for the treatment of osteoarthritis.

Janusz MJ, Hookfin EB, Brown KK, Hsieh LC, Heitmeyer SA, Taiwo YO, Natchus MG, Pikul S, Almstead NG, De B, Peng SX, Baker TR, Patel V.

Inflamm Res. 2006 Feb;55(2):60-5.

PMID:
16612565
19.

Development of orally bioavailable bicyclic pyrazolones as inhibitors of tumor necrosis factor-alpha production.

Clark MP, Laughlin SK, Laufersweiler MJ, Bookland RG, Brugel TA, Golebiowski A, Sabat MP, Townes JA, VanRens JC, Djung JF, Natchus MG, De B, Hsieh LC, Xu SC, Walter RL, Mekel MJ, Heitmeyer SA, Brown KK, Juergens K, Taiwo YO, Janusz MJ.

J Med Chem. 2004 May 20;47(11):2724-7.

PMID:
15139749
20.

The development of new triazole based inhibitors of tumor necrosis factor-alpha (TNF-alpha) production.

Tullis JS, VanRens JC, Natchus MG, Clark MP, De B, Hsieh LC, Janusz MJ.

Bioorg Med Chem Lett. 2003 May 19;13(10):1665-8.

PMID:
12729637
21.

Moderation of iodoacetate-induced experimental osteoarthritis in rats by matrix metalloproteinase inhibitors.

Janusz MJ, Hookfin EB, Heitmeyer SA, Woessner JF, Freemont AJ, Hoyland JA, Brown KK, Hsieh LC, Almstead NG, De B, Natchus MG, Pikul S, Taiwo YO.

Osteoarthritis Cartilage. 2001 Nov;9(8):751-60.

22.

Potent and selective carboxylic acid-based inhibitors of matrix metalloproteinases.

Pikul S, Ohler NE, Ciszewski G, Laufersweiler MC, Almstead NG, De B, Natchus MG, Hsieh LC, Janusz MJ, Peng SX, Branch TM, King SL, Taiwo YO, Mieling GE.

J Med Chem. 2001 Aug 2;44(16):2499-502. No abstract available.

PMID:
11472202
23.

The development of new carboxylic acid-based MMP inhibitors derived from a cyclohexylglycine scaffold.

Tullis JS, Laufersweiler MJ, VanRens JC, Natchus MG, Bookland RG, Almstead NG, Pikul S, De B, Hsieh LC, Janusz MJ, Branch TM, Peng SX, Jin YY, Hudlicky T, Oppong K.

Bioorg Med Chem Lett. 2001 Aug 6;11(15):1975-9.

PMID:
11454461
24.

Heterocycle-based MMP inhibitors with P2' substituents.

Pikul S, Dunham KM, Almstead NG, De B, Natchus MG, Taiwo YO, Williams LE, Hynd BA, Hsieh LC, Janusz MJ, Gu F, Mieling GE.

Bioorg Med Chem Lett. 2001 Apr 23;11(8):1009-13.

PMID:
11327577
25.

Development of new carboxylic acid-based MMP inhibitors derived from functionalized propargylglycines.

Natchus MG, Bookland RG, Laufersweiler MJ, Pikul S, Almstead NG, De B, Janusz MJ, Hsieh LC, Gu F, Pokross ME, Patel VS, Garver SM, Peng SX, Branch TM, King SL, Baker TR, Foltz DJ, Mieling GE.

J Med Chem. 2001 Mar 29;44(7):1060-71.

PMID:
11297453
26.

Chemoenzymatic synthesis of functionalized cyclohexylglycines and alpha-methylcyclohexylglycines via Kazmaier-Claisen rearrangement.

Hudlicky T, Oppong K, Duan C, Stanton C, Laufersweiler MJ, Natchus MG.

Bioorg Med Chem Lett. 2001 Mar 12;11(5):627-9.

PMID:
11266157
27.

Development of new hydroxamate matrix metalloproteinase inhibitors derived from functionalized 4-aminoprolines.

Natchus MG, Bookland RG, De B, Almstead NG, Pikul S, Janusz MJ, Heitmeyer SA, Hookfin EB, Hsieh LC, Dowty ME, Dietsch CR, Patel VS, Garver SM, Gu F, Pokross ME, Mieling GE, Baker TR, Foltz DJ, Peng SX, Bornes DM, Strojnowski MJ, Taiwo YO.

J Med Chem. 2000 Dec 28;43(26):4948-63.

PMID:
11150165
28.

Automated 96-well SPE and LC-MS-MS for determination of protease inhibitors in plasma and cartilage tissues.

Peng SX, King SL, Bornes DM, Foltz DJ, Baker TR, Natchus MG.

Anal Chem. 2000 Apr 15;72(8):1913-7.

PMID:
10784161
29.

Design and synthesis of piperazine-based matrix metalloproteinase inhibitors.

Cheng M, De B, Pikul S, Almstead NG, Natchus MG, Anastasio MV, McPhail SJ, Snider CE, Taiwo YO, Chen L, Dunaway CM, Gu F, Dowty ME, Mieling GE, Janusz MJ, Wang-Weigand S.

J Med Chem. 2000 Feb 10;43(3):369-80.

PMID:
10669564
30.

Design, synthesis, and biological evaluation of matrix metalloproteinase inhibitors derived from a modified proline scaffold.

Cheng M, De B, Almstead NG, Pikul S, Dowty ME, Dietsch CR, Dunaway CM, Gu F, Hsieh LC, Janusz MJ, Taiwo YO, Natchus MG, Hudlicky T, Mandel M.

J Med Chem. 1999 Dec 30;42(26):5426-36.

PMID:
10639284
31.

Design, synthesis, and biological evaluation of potent thiazine- and thiazepine-based matrix metalloproteinase inhibitors.

Almstead NG, Bradley RS, Pikul S, De B, Natchus MG, Taiwo YO, Gu F, Williams LE, Hynd BA, Janusz MJ, Dunaway CM, Mieling GE.

J Med Chem. 1999 Nov 4;42(22):4547-62.

PMID:
10579818
32.

The next generation of MMP inhibitors. Design and synthesis.

De B, Natchus MG, Cheng M, Pikul S, Almstead NG, Taiwo YO, Snider CE, Chen L, Barnett B, Gu F, Dowty M.

Ann N Y Acad Sci. 1999 Jun 30;878:40-60. Review.

PMID:
10415719
33.

Design and synthesis of phosphinamide-based hydroxamic acids as inhibitors of matrix metalloproteinases.

Pikul S, McDow Dunham KL, Almstead NG, De B, Natchus MG, Anastasio MV, McPhail SJ, Snider CE, Taiwo YO, Chen L, Dunaway CM, Gu F, Mieling GE.

J Med Chem. 1999 Jan 14;42(1):87-94.

PMID:
9888835
34.

Design and synthesis of conformationally-constrained MMP inhibitors.

Natchus MG, Cheng M, Wahl CT, Pikul S, Almstead NG, Bradley RS, Taiwo YO, Mieling GE, Dunaway CM, Snider CE, McIver JM, Barnett BL, McPhail SJ, Anastasio MB, De B.

Bioorg Med Chem Lett. 1998 Aug 18;8(16):2077-80.

PMID:
9873489
35.

Discovery of potent, achiral matrix metalloproteinase inhibitors.

Pikul S, McDow Dunham KL, Almstead NG, De B, Natchus MG, Anastasio MV, McPhail SJ, Snider CE, Taiwo YO, Rydel T, Dunaway CM, Gu F, Mieling GE.

J Med Chem. 1998 Sep 10;41(19):3568-71. No abstract available.

PMID:
9733482

Supplemental Content

Loading ...
Support Center